← Trials/Trial dossier/NCT00835848

POSTCON II

CompletedPhase 4

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI

Lead sponsor

Rigshospitalet, Denmark

Asset

Exenatide

Intravenous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

100

estimated

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•Infarct size by MRI

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00835848

Org study IDKF 01 326257 b

Timeline

Milestones

Study first posted2009-02-04estimated

Last update posted2015-05-05estimated

Study start2009-01 (month precision)

Primary completion2009-12actual (month precision)

Study completion2015-05actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•More than 18 years of age.

•STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of >0.1 mV in V4 - V6 or limb leads II, III and aVF, or >0.2 mV in lead V1 - V3.

•TIMI 0-1 in infarct related artery.

•Oral and written informed consent.

Exclusion criteria

•Multivessel disease defined by one or more stenoses >70% in diameter in the non infarct related artery.

•Previous myocardial infarction.

•Stent trombosis.

•Previous CABG.

•Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.

•Renal insufficiency (creatinin >200).

•Pregnancy or lactation.

•Diabetic ketoacidose eller hypoglycemia (plasma glukose < 2.5 mmol/l).

•Pancreatitis.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiovascular outcomes

2 endpoints

Primary/protocol endpoint

Infarct size by MRI

Time frame:3 months

descriptive, improvement

Secondary/protocol endpoint

Cardiel death after 1 and 15 months.

Time frame:15 months

Cardiovascular death

time to event, event

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.
Annals of medicine2017 Nov (month)PMID28286967doi:10.1080/07853890.2017.1306653via clinicaltrials gov reference derived + pubmed nct search
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
European heart journal2012 Jun (month)PMID21920963doi:10.1093/eurheartj/ehr309via clinicaltrials gov reference derived + pubmed nct search
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Circulation. Cardiovascular interventions2012 Apr (month)PMID22496084doi:10.1161/CIRCINTERVENTIONS.112.968388via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.